Send to

Choose Destination
Clin Transl Sci. 2018 Jul;11(4):397-404. doi: 10.1111/cts.12548. Epub 2018 Mar 25.

Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers.

Author information

Division of Nuclear Medicine, Department of Imaging and Pathology, University Hospital and KU Leuven, Leuven, Belgium.
MEPhI National Research Nuclear University, Moscow, Russia.
Neuroscience Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Department of Pharmaceutical and Pharmacological Sciences, Center for Clinical Pharmacology, University Hospitals of Leuven, Leuven, Belgium.
Clinical Pharmacology Unit, Janssen Research & Development, Merksem, Belgium.
Janssen Research & Development, Titusville, New Jersey, USA.
Janssen Research & Development, Beerse, Antwerp, Belgium.
Janssen Research & Development, San Diego, California, USA.
Janssen Research & Development, Spring House, Pennsylvania, USA.
Laboratory of Radiopharmaceutical Research of the KU Leuven, Leuven, Belgium.


Inhibition of fatty acid amide hydrolase (FAAH) potentiates endocannabinoid activity and is hypothesized to have therapeutic potential for mood and anxiety disorders and pain. The clinical profile of JNJ-42165279, an oral selective FAAH inhibitor, was assessed by investigating the pharmacokinetics, pharmacodynamics, safety, and binding to FAAH in the brain of healthy human volunteers. Concentrations of JNJ-42165279 (plasma, cerebrospinal fluid (CSF), urine) and fatty acid amides (FAA; plasma, CSF), and FAAH activity in leukocytes was determined in a phase I multiple ascending dose study. A positron emission tomography study with the FAAH tracer [11 C]MK3168 was conducted to determine brain FAAH occupancy after single and multiple doses of JNJ-42165279. JNJ-42165279 administration resulted in an increase in plasma and CSF FAA. Significant blocking of brain FAAH binding of [11 C]MK3168 was observed after pretreatment with JNJ-42165279. JNJ-42165279 produces potent central and peripheral FAAH inhibition. Saturation of brain FAAH occupancy occurred with doses ≥10 mg of JNJ-42165279. No safety concerns were identified.

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center